Co-Diagnostics Targets European Expansion with ESCMID 2026 Showcase
Event summary
- Co-Diagnostics will exhibit at ESCMID Global 2026 in Munich (April 17-21), targeting 16,000+ attendees.
- Company will showcase CE-IVD testing solutions and its upcoming Co-Dx PCR platform (not yet FDA-approved).
- Aims to strengthen international commercial relationships with global customers and distributors.
- Booth #G55 will serve as the primary engagement point for potential partners.
The big picture
Co-Diagnostics' participation in ESCMID 2026 underscores its push into European markets, where demand for advanced infectious disease diagnostics remains strong. The event provides a critical platform to validate its CE-IVD solutions and gauge interest in its upcoming Co-Dx PCR platform, which could expand its addressable market if regulatory hurdles are cleared. Success here would position the company as a key player in decentralized molecular diagnostics.
What we're watching
- Regulatory Timelines
- The pace at which Co-Diagnostics secures FDA approval for its Co-Dx PCR platform will determine its commercial viability.
- Market Penetration
- Whether the company can convert ESCMID engagement into meaningful international partnerships.
- Competitive Positioning
- How Co-Diagnostics differentiates its CE-IVD solutions in a crowded European diagnostics market.